PMID- 36404867
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230619
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 21
IP  - 2
DP  - 2022 Dec
TI  - Nesfatin-1 - as a diagnosis regulatory peptide in type 2 diabetes mellitus.
PG  - 1369-1375
LID - 10.1007/s40200-022-01070-8 [doi]
AB  - BACKGROUND: One of the most common metabolic diseases, Type 2 Diabetes Mellitus 
      (T2DM), is caused by a combination of two basic factors: insufficient insulin 
      secretion by pancreatic -cells or a failure of insulin-sensitive tissues to 
      respond adequately to insulin. The aim of this paper was to assess the diagnostic 
      accuracy of serum nesfatin-1 in type 2 diabetes mellitus (T2DM). METHODS: Sixty 
      patients with T2DM were recruited from (Baquba Teaching Hospital) in Iraq during 
      the period (from November 2021 - March 2022). T2DM group was classified into 30 
      newly diagnosis patients (without treatment) and 30 ongoing diabetic patients 
      (with treatment) for comparison, as well 30 healthy individuals were included as 
      a control. The ELISA Kit was used to measure serum nesfatin-1 and serum insulin, 
      fasting serum glucose, and lipid profile test were measured through 
      spectrophotometric, instead of HbA1c was determined using HPLC method. RESULTS: 
      The concentration of serum nesfatin-1 in the T2DM group was significantly lower 
      than that of the healthy subjects (p < 0.05). There was a significant difference 
      in the serum nestafin-1 concentrations between newly diagnosis and ongoing T2DM 
      patients. There were substantial negative connections between serum Nesfatin-1 
      concentration and HOMA-IR, as well as strong negative correlations between serum 
      nesfatin-1 and serum insulin level. The concentration of serum Nesfatin-1, on the 
      other hand, had no significant association with the anthropometries measurements 
      and biochemical parameters. The area under the curve was excellent (AUC = 0.827, 
      p = 0.0001), with high diagnostic accuracy (86.2) in differentiating newly 
      diagnosis T2DM from the healthy subject group. CONCLUSION: Nesfatin-1 levels in 
      the sera of diabetic patients was shown to be lower and nesfatin-1 levels were 
      shown to be significantly linked to newly diagnosed patients.
CI  - (c) The Author(s), under exclusive licence to Tehran University of Medical Sciences 
      2022.
FAU - Kadim, Bushra Mussad
AU  - Kadim BM
AD  - Department of Chemistry, College of Science, University of Diyala, Baquba, Diyala 
      Iraq. GRID: grid.442846.8. ISNI: 0000 0004 0417 5115
FAU - Hassan, Ekhlas Abdallah
AU  - Hassan EA
AUID- ORCID: 0000-0001-7655-6230
AD  - Department of Chemistry, College of Science, University of Diyala, Baquba, Diyala 
      Iraq. GRID: grid.442846.8. ISNI: 0000 0004 0417 5115
LA  - eng
PT  - Journal Article
DEP - 20220618
PL  - Switzerland
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC9672287
OTO - NOTNLM
OT  - HOMA-IR
OT  - Nesfatin-1
OT  - Serum insulin
OT  - Type 2 diabetes mellitus
COIS- Competing interestThe authors state that they have no known competing financial 
      or personal interests that could have influenced the findings presented in this 
      research.
EDAT- 2022/11/22 06:00
MHDA- 2022/11/22 06:01
PMCR- 2023/06/18
CRDT- 2022/11/21 03:45
PHST- 2022/01/26 00:00 [received]
PHST- 2022/06/08 00:00 [accepted]
PHST- 2022/11/21 03:45 [entrez]
PHST- 2022/11/22 06:00 [pubmed]
PHST- 2022/11/22 06:01 [medline]
PHST- 2023/06/18 00:00 [pmc-release]
AID - 1070 [pii]
AID - 10.1007/s40200-022-01070-8 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2022 Jun 18;21(2):1369-1375. doi: 
      10.1007/s40200-022-01070-8. eCollection 2022 Dec.